PFE - Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally The Pivot Investors Have Been Waiting For' | Benzinga
Pfizer Inc (NYSE:PFE) reported first-quarter earnings Wednesday with adjusted EPS of 82 cents. That’s down 33% year-over-year, beating the consensus of 54 cents.
The New York-based company witnessed a significant decrease in Comirnaty and Paxlovid revenues globally and an unfavorable impact of foreign exchange of $107 million, or 1%.
The U.S. drugmaker reported sales of $14.9 billion, down 20%, beating the consensus of $14.2 billion.
- Goldman Sachs maintains the Buy rating with a price target of $31.
- BMO Capital raises the price target from $33 to $36 and reiterates the Outperform rating
- Bank of America Securities maintains a Neutral rating with a price target of $35.
Goldman Sachs: Pfizer shares outperformed after the earnings and interprets the Paxlovid beat ...